Figure AI broke up with OpenAI, Novo Nordisk showed off a healthier frame, and the microplastics in your brain |
Finimize

Hi John, here's what you need to know for February 6th in 3:15 minutes.

  1. Figure AI made a major breakthrough in humanoid development
  2. If you’ve got $10,000 lying around, here’s where the pros would invest it – Read Now
  3. Weight-loss drugmaker Novo Nordisk showed off its own new-and-improved results, reporting better-than-expected sales

🪙 Crypto could change dramatically this year – for better or for worse. Join Morpher's co-founder and chief executive officer for The Rise Of Cryptocurrency In 2025 on March 24th, and discover the factors shaping the future of digital coins. Get your free ticket

Go Figure
Go Figure

What’s going on here?

Robotics company Figure AI – valued last year at $2.6 billion – ditched its collaboration with OpenAI, determined to work out the whole “humanoids taking over the world” thing alone.

What does this mean?

Figure has quite the support network, counting Microsoft, Nvidia, and Jeff Bezos’ Explore Investments as backers. And with plenty of shoulders to lean on, the robotics firm has decided it can afford to bow out of its partnership with OpenAI. Instead, Figure will focus on its in-house system – which, it just so happens, has reached a point of “major breakthrough”. The company has said that in the next month, it’ll showcase “something no one has ever seen on a humanoid”. Let’s hope it’s not a desire to watch the world burn: Figure’s on track to make 100,000 robots over the next four years.

Why should I care?

Zooming in: Welcome to Stepford.

The act of giving life – or, uh, integrating AI into physical objects like robots – produces aptly named “embodied AI” systems. Now, that isn’t OpenAI’s primary focus by any means. But clearly, the industry’s whizz kid doesn’t want to miss a trick. Despite the colossal costs that come with this type of development, OpenAI recently applied for patents concerning humanoid hardware. Plus, the firm’s a major investor in 1X – a Norwegian robotics startup focused on building humanoids for home use.

The bigger picture: Hi, Robot.

The top dogs at Tesla and Nvidia have both praised humanoids as the next major opportunity in the AI space. Elon Musk has laid – self-described – ambitious plans to build 10,000 robots this year. He estimates the walking, talking tech could bring in more than $10 trillion over the long term, easily enough to become the most valuable arm of Tesla’s business. But only time (and a lot of it) will tell if the robots can deliver… if they don’t go all “Terminator” on us first, that is.

Copy to share story: https://app.finimize.com/content/go-figure

🙋 Ask a question

TODAY'S INSIGHT

How Top Investors Would Put $10,000 To Work Right Now

Russell Burns

How Top Investors Would Put $10,000 To Work Right Now

Let’s say you’ve just scored a sweet $10,000 windfall. Congrats on that, by the way.

Now, you could play it safe and park that beautiful stack of bills in a money-market fund, where you could earn a steady, risk-free 4.3% a year.

But if you’re open to taking on a little more risk for the chance at bigger returns, three investing experts have just shared their top ideas with Bloomberg.

So let’s check out where they’d stash ten grand right now – and I’ll give you my take on each notion.

That’s today’s Insight: what to do with $10,000 if it’s just burning a hole in your pocket.

Read or listen to the Insight here

* SPONSORED BY SAXO

One platform, 18,000-plus investment opportunities, and market-leading prices 

You might’ve cancelled your gym membership and stopped packing lunches for work.

But one resolution should be easy to stick to this year: save more money. With a tax-free stocks and shares ISA, you could see your savings compound faster than in a taxed alternative.

Plenty of Brits have already put their money to work and seen the reward: there are now nearly 5,000* ISA millionaires in the UK, more than ever before.

This year, put yourself on track to join them. With Saxo, you can invest in over 18,000 assets – you’ll be hard-pressed to find more elsewhere – at market leading prices.

Its parent company, Saxo Bank A/S, boasts an A- S&P credit rating and 1.2 million global customers, who entrust it with over €100 billion of their hard-earned money.

So, if you’re working your way toward a seven-figure savings account, check out Saxo, the award-winning platform – equipped with in-house experts.

Find Out More

Disclaimers:

Capital at risk. Tax treatment depends on individual circumstance and may be subject to change. 

*Data from HMRC, Apr 24.

When you support our sponsors, you support us. Thanks for that.

If you want your brand featured here, get in touch.

Move The Needle
Move The Needle

What’s going on here?

Novo Nordisk reported better-than-expected results on Wednesday, and that might nudge more investors toward Europe’s most valuable listed company.

What does this mean?

Novo’s insulin products have been flying off the pharmacy shelves – so much so that last quarter’s sales were 5% higher than expected. That meant the Danish drugmaker’s sales were 26% higher in 2024 than 2023. And that should reassure investors who were starting to stray. See, Novo’s latest products delivered disappointing results in trials last year, and the firm’s been fighting off increasingly tough competition. As a result, investors had pushed the stock down 40% between last summer’s peak and the start of this week. But thanks to those solid sales figures and a forecast of up to 24% more revenue this year, Novo’s shares were lifted by a welcome 5% after the news.

Why should I care?

For markets: Bigger isn’t always better.

Even though Novo’s shares are down from their peak, the firm is – arguably – the most dominant weight-loss drugmaker. And because investors know it, the firm’s stock is still far from affordable. Ditto for rival Eli Lilly’s shares. Sure, plenty of smaller biotech companies are working on their own equivalents, but it’ll be years before those drugs hit the market – and until then, there’s no telling which ones will be most popular. So if you’re looking to buy into the weight-loss theme, you might want to branch out beyond the talked-about injections. You could consider gyms, activewear brands, healthy food products, and health insurers. Remember, as folk focus more on their waistlines, they’ll make other lifestyle changes too – leading them straight into the arms of those sorts of companies. Meanwhile, those that churn out junk food, sugary drinks, and booze could be forced to bid adieu to formerly loyal customers. Just look at Diageo: shares in the alcoholic drinks firm have fallen by 26% over the past five years.

Copy to share story: https://app.finimize.com/content/move-the-needle

🙋 Ask a question

QUOTE OF THE DAY

"We consume our tomorrows fretting about our yesterdays."

– Persius (a Roman poet and satirist)
Tweet this
* SPONSORED BY SWISSBORG

You could back the next big crypto token

The crypto market has seen its share of winning assets.

And while there are a lot of big names out there already, that doesn’t mean there isn’t room for smaller players.

In fact, several promising early-stage crypto projects are in the works. And they’re working with SwissBorg to raise funding – from retail investors like you. 

Now, you’re probably wondering why these projects don’t seek VC funding. The answer: it’s expensive, and it brings a third party into the mix. These projects want to keep it in the family and have their users become investors, and vice versa.

That means you could get in on the high-risk, high-potential-reward opportunities. And if you sign up with code SBFIN15 and trade €100 ($103) this month, SwissBorg will give you a cool €15.

Visit SwissBorg to check out the tokens you could get behind.

Find Out More

When you support our sponsors, you support us. Thanks for that.

If you want your brand featured here, get in touch.

🎯 On Our Radar

1. That's no spoonful of sugar. Turns out your brain is full of microplastics.

2. Decode the numbers behind your trades. Find out how the "Greeks" can give you an edge in real-world market moves.*

3. Forget about making new friends. If you want some company, consider adopting grandparents.

4. A golden oldie. How to invest in one of the world's oldest investments with GoldCore.*

5. Maybe a DMC isn't enough. Here's how to tell your friend they might need therapy.

When you support our sponsors, you support us. Thanks for that.

🌍 Finimize Live

🤩 Grab your tickets...

(All events in UK time)

🤖 Investing Beyond AI: 5pm, February 24th

💰 How To Build Your Passive Income Playbook: 5pm, March 11th

🚀 The Rise Of Cryptocurrency In 2025: 5pm, March 24th

🙌 Your Guide To Flexible ISAs*: 5pm, April 8th

*Events designed for UK investors

Thanks for reading John. If you liked today’s brief, we’d love for you to share it with a friend – here’s a link: Share this email

You stay classy, John 😉

Any thoughts on today’s email? Give feedback

Want to advertise with us? Get in touch

Image credits: Midjourney | Midjourney

Preferences:

Update your email or change preferences

View in browser

Unsubscribe from all Finimize Emails

Crafted by Finimize Ltd. | 280 Bishopsgate, London, EC2M 4AG

All content provided by Finimize Ltd. is for informational and educational purposes only and is not meant to represent trade or investment recommendations. You signed up to this mailing list at finimize.com or through one of our partners. © Finimize 2024

View Online

When you support our sponsors, you support us. Thanks for that.